Patents by Inventor Benoît Villiers

Benoît Villiers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-methylcrotonic acid decarboxylase (MDC) variants
    Patent number: 11293016
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: April 5, 2022
    Assignee: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • 3-methylcrotonic acid decarboxylase (MDC) variants
    Patent number: 10988752
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: April 27, 2021
    Assignee: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS
    Publication number: 20210102186
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Applicant: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • 3-methylcrotonic acid decarboxylase (MDC) variants
    Patent number: 10808237
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 20, 2020
    Assignee: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS
    Publication number: 20190322996
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Applicant: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS
    Publication number: 20190100742
    Abstract: Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants.
    Type: Application
    Filed: October 5, 2018
    Publication date: April 4, 2019
    Applicant: Global Bioenergies
    Inventors: François Stricher, Benoît Villiers
  • HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway
    Patent number: 9758552
    Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: September 12, 2017
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
  • HB-EGF INHIBITOR DERIVED FROM THE R DOMAIN OF DIPHTHERIA TOXIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF THE HB-EGF/EGFR PATHWAY
    Publication number: 20150051146
    Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT
    Inventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson